

PTO/SB/08a/b (06-03)
Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO 09/891093 Application Number INFORMATION DISCLOSURE June 25, 2001 Filing Date STATEMENT BY APPLICANT First Named Inventor Sidney Pestka Art Unit 1646 (Use as many sheets as necessary) P. Mertz Examiner Name PBLI-P08-005 Attorney Docket Number Sheet 1 1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁸ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	ВХ	Baldwin, C. T. et al. A Single Base Mutation that Converts Glycine 907 of the α2(I) Chain of Type I Procollagen to Asparate in a Lethal Variant of Osteogenesis Imperfecta. <i>J. Biol. Chem.</i> 264, 3002-3006 (15 February 1989).	
	BY	Cohen, S. et al. Cloning, expression, and biological activity of a new variant of human interferon alpha identified in virus induced lymphoblastoid cells. <i>Developments in Biological Standardization</i> 60, 111-122 (1985).	
	BZ	Cunnigham et al. High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis. <i>Science</i> 244, 1081-1085 (1989).	
	CA	Goeddel, D.V. et al. The structure of eight distinct cloned human leukocyte interferon cDNAs. <i>Nature</i> 290, 20-26 (1981).	
	СВ	Hinds, M. et al. Identification of a Point Mutation in the Topoisomerase II Gene from a Human Leukemia Cell Line Containing an Amsacrine-resistant Form of Topoisomerase. <i>Cancer Res.</i> 51, 4729-4731 (1 Sept. 1991).	
	СС	Ledley, F.D. et al. Molecular basis of alphal-antitryssin deficiency and its potential therapy by gene transfer. <i>J. Inherited Metabolism Disease</i> 9, Supp. 1: 85-91 (1986).	
	CD	Wong, A.J. et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. <i>PNAS</i> 89: 2965-2969 (1992).	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.